« Return to News | R&D Trends

Soligenix awarded NIAID contract

Wednesday, October 2, 2013 01:14 PM

Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures (MCMs) for which there remains an unmet medical need, has been awarded a contract valued at up to $6.4 million by the U.S. Department of Health and Human Service's NIH (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID).

The contract is for the advanced preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP) as an MCM for the treatment of gastrointestinal acute radiation syndrome (GI ARS). ARS occurs after toxic radiation exposure and involves several organ systems, notably the bone marrow the GI tract and, later, the lungs.   In the event of a nuclear disaster or terrorist detonation of a nuclear bomb, casualties exposed to >2 Gy are at high risk for development of clinically significant ARS. The potential three-year contract contains a one-year base period, with two one-year contract extension options.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.